3TC

This brand name is authorized in Australia, Canada, Hong Kong, New Zealand

Active ingredients

The drug 3TC contains one active pharmaceutical ingredient (API):

1 Lamivudine UNII 2T8Q726O95 - LAMIVUDINE

Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription. Read about Lamivudine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
Lamivudine 3TC Tablets	Health Products and Food Branch (CA)	MPI, CA: SPM

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AF05	Lamivudine	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
Discover more medicines within J05AF05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10311Q, 10320E, 10348P
Country: CA	Health Products and Food Branch	Identifier(s): 02192683, 02192691, 02247825
Country: HK	Department of Health Drug Office	Identifier(s): 42074, 53149, 64798
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 7596, 7597, 9939